Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients

Treatment of metastatic kidney cancer has changed dramatically in the past years with the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance occurs. We report here two cases of patients who benefited, both on disease control and side effects, from the addition of bevacizumab to...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyle, H., Négrier, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2011
Materias:
Published: November, 2011
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237108/
https://www.ncbi.nlm.nih.gov/pubmed/22171218
http://dx.doi.org/10.1159/000334581
Descripción
Sumario:Treatment of metastatic kidney cancer has changed dramatically in the past years with the use of VEGF-targeted therapies and mTOR inhibitors. However, resistance occurs. We report here two cases of patients who benefited, both on disease control and side effects, from the addition of bevacizumab to temsirolimus, after progression on the mTOR inhibitor alone.

Ejemplares similares